Clinical Study of Pyrotinib in Neoadjuvant Therapy of HR-positive and HER2-positive Breast Cancer

NCT05430347 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

COMBINATION_PRODUCT: Neoadjuvant therapy: TCbHPy
COMBINATION_PRODUCT: Neoadjuvant therapy: TCbHP

Sponsor

The First Affiliated Hospital with Nanjing Medical University